Epizyme Inc (NASDAQ:EPZM) saw a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 7,444,000 shares, an increase of 17.3% from the June 15th total of 6,346,400 shares. Approximately 12.8% of the shares of the company are sold short. Based on an average trading volume of 886,200 shares, the days-to-cover ratio is presently 8.4 days.

Several research firms recently issued reports on EPZM. Zacks Investment Research cut German American Bancorp. from a “buy” rating to a “hold” rating in a research report on Tuesday, April 30th. Citigroup set a $14.00 target price on Coty and gave the stock a “hold” rating in a research report on Thursday, May 30th. HC Wainwright set a $126.00 target price on AnaptysBio and gave the stock a “buy” rating in a research report on Monday, June 24th. Wedbush reiterated an “outperform” rating and set a $21.00 target price on shares of Epizyme in a research report on Wednesday, June 12th. Finally, BidaskClub cut Xencor from a “sell” rating to a “strong sell” rating in a research report on Tuesday, June 11th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $18.90.

In other Epizyme news, CEO Robert B. Bazemore sold 2,074 shares of the company’s stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $12.10, for a total value of $25,095.40. Following the completion of the sale, the chief executive officer now owns 87,068 shares in the company, valued at $1,053,522.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director David M. Mott sold 104,944 shares of the company’s stock in a transaction dated Wednesday, June 26th. The stock was sold at an average price of $13.08, for a total value of $1,372,667.52. Following the completion of the sale, the director now owns 13,979 shares of the company’s stock, valued at approximately $182,845.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 108,203 shares of company stock valued at $1,412,101. 16.60% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. JGP Global Gestao de Recursos Ltda. increased its holdings in Epizyme by 10.4% during the 1st quarter. JGP Global Gestao de Recursos Ltda. now owns 13,691 shares of the biopharmaceutical company’s stock worth $170,000 after purchasing an additional 1,293 shares during the period. Legal & General Group Plc increased its holdings in Epizyme by 16.9% during the 4th quarter. Legal & General Group Plc now owns 10,060 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 1,455 shares during the period. Metropolitan Life Insurance Co NY increased its holdings in Epizyme by 18.3% during the 1st quarter. Metropolitan Life Insurance Co NY now owns 19,570 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 3,029 shares during the period. American International Group Inc. increased its holdings in Epizyme by 13.0% during the 4th quarter. American International Group Inc. now owns 39,223 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 4,513 shares during the period. Finally, Exane Derivatives purchased a new position in Epizyme during the 1st quarter worth $84,000. Institutional investors own 84.14% of the company’s stock.

Shares of NASDAQ:EPZM traded down $0.09 during trading on Friday, hitting $13.41. The company had a trading volume of 665,967 shares, compared to its average volume of 784,065. The company has a market cap of $1.22 billion, a PE ratio of -7.80 and a beta of 2.46. Epizyme has a one year low of $5.14 and a one year high of $16.59. The stock has a fifty day moving average price of $13.26. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.55 and a current ratio of 12.55.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.07. The business had revenue of $7.89 million during the quarter, compared to analysts’ expectations of $1.13 million. As a group, research analysts anticipate that Epizyme will post -2 EPS for the current year.

Epizyme Company Profile

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

Further Reading: How to Track your Portfolio in Google Finance

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.